AKEBIA THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $85.00K, a 52.25% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $20.00K, a 95.85% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $962.00K.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $178.00K, a 1171.43% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $1.68M, a 336.27% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $386.00K, a 38500.00% increase from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $1.00K, a 98.51% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $67.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $85.00K 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $20.00K 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $1.68M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $962.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $178.00K 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $482.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $386.00K 10-K · filed 2026-02-26 | |
| 2024-06-30 | $14.00K 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $141.00K 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $1.00K 10-K · filed 2026-02-26 | |
| 2022-12-31 | $67.00K 10-K · filed 2024-03-14 | |
| 2022-06-30 | $67.00K 10-Q · filed 2023-11-08 | |
| 2020-12-31 | $1.23M 10-K/A · filed 2023-08-28 | |
| 2020-09-30 | $405.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $409.00K 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $412.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $560.00K 10-K · filed 2022-03-01 | |
| 2019-06-30 | $195.00K 10-Q · filed 2020-11-05 | $711.00K derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-03-31 | $365.00K 10-Q · filed 2020-11-05 | $830.00K derived: sum of 4 quarters · filed 2020-11-05 |
| 2018-12-31 | $92.00K 10-Q · filed 2019-05-09 | $647.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | $59.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $314.00K 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $182.00K 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $1.31M 10-K · filed 2020-03-12 | |
| 2016-12-31 | $124.00K 10-K · filed 2019-03-26 | |
| 2015-12-31 | $130.00K 10-K · filed 2018-03-12 | |
| 2014-12-31 | $89.00K 10-K · filed 2017-03-06 | |
| 2013-12-31 | $5.00K 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |